J 2026

Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis

AMMIRATI, Enrico; Matteo PALAZZINI; Jukka LEHTONEN; Luciano POTENA; Mikko I MAYRANPAA et al.

Základní údaje

Originální název

Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis

Autoři

AMMIRATI, Enrico; Matteo PALAZZINI; Jukka LEHTONEN; Luciano POTENA; Mikko I MAYRANPAA; Johanna RAGBACK; Alberto FOA; Aitor URIBARRI; Holger THIELE; Maria VIDAL-BURDEUS; Anne FREUND; Finn GUSTAFSSON; Carsten TSCHOPE; Ahmed ELSANHOURY; Joshua IHLE; Wolf-Stephan RUDI; Ulrich GRABMAIER; Marco MERLO; Vojtech MELENOVSKY; Ivana WEISLOVA; Stefanie JELLINGHAUS; Axel LINKE; Chiara BALDOVINI; Rachele ADORISIO; Petr KUCHYNKA; Tomas PALECEK; Jan KREJČÍ; Hana POLOCZKOVÁ; Anna Laura CATERINO; Nisha A GILOTRA; Jana P LOVELL; Elaine P MACOMB; Jeffrey SHIH; Kimberly HONG; Valentina A ROSSI; Frank RUSCHITZKA; Claudio CAVALLINI; Clara RICCINI; Mohamed KAMAL; Florent HUANG; Matthieu GROH; Piero GENTILE; Andrea GARASCIA; Anuradha LALA; Hiroaki SHIMOKAWA; Christophe VANDENBRIELE; Alessandro SIONIS; Matthieu SCHMIDT; Aurelia GROSU; Entela BOLLANO; Annalisa TURCO; Maria G CRESPO-LEIRO; David COUTO-MALLON; Antonio CANNATA; Daniel I BROMAGE; Maria Lucia NARDUCCI; Vincenzo CICCHITTI; Umberto IANNI; De Luca LEONARDO; Raffaella MISTRULLI; Simone FREA; Claudia RAINERI; Jan W SCHROEDER; Anibal Martin ARIAS; Michele EMDIN; Marco CORDA; Daniele PASQUALUCCI; Simon GREULICH; Meinrad GAWAZ; Tatiana MANUYLOVA; Manuel MARTINEZ-SELLES; Hernandez Perez Francisco JOSE; Martin Centellas ALBA; Fernando DOMINGUEZ; Antoine GAILLET; Nicoletta D'ALESSANDRIS; Cory TRANKLE; Marc K HALUSHKA; Francesco MORONI; Antonio ABBATE; Cristina BASSO; Gianfranco SINAGRA; Giacomo VERONESE; Paolo G CAMICI; Eric D ADLER; Davide P BERNASCONI; Karin KLINGEL a Leslie T COOPER

Vydání

Circulation, Philadelphia, Lippincott Williams Wilkins, 2026, 0009-7322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 38.600 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

biopsy; Churg-Strauss syndrome; eosinophilia; hypersensitivity; myocarditis; treatment outcome

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 5. 5. 2026 14:17, Mgr. Tereza Miškechová

Anotace

V originále

BACKGROUND: No large registries of patients with acute eosinophilic myocarditis (EM) are available. However, EM is perceived as a cardiac disease with high mortality, affecting mainly young and middle-aged adults according to small series and case reports. Awareness of the clinical presentation, associated systemic conditions, treatments, and outcomes of this uncommon condition is an unmet need. METHODS: In this international, multicenter, retrospective cohort study, 53 centers screened 193 patients with histologically proven acute EM between 1992 and 2023. After the exclusion of patients with insufficient data (n=10), symptoms lasting >30 days (n=19), or histological diagnosis not confirmed after review (n=8), 156 patients were included. RESULTS: Median age at presentation was 48 years (quartile 1-3, 34-59 years) with male predominance (67.3%), and only 2 were pediatric cases (<= 16 years of age; 1.3%). The main signs and symptoms at presentation were dyspnea (75.6%), fever (61.3%), and chest pain (53.2%). Unexpectedly, peripheral eosinophilia was reported in only 57.4% of cases, with a median cell count of 630 eosinophils/mu L. The median left ventricular ejection fraction at presentation was 32% (quartile 1-3, 25%-48%). The disorders most frequently associated with EM were eosinophilic granulomatosis with polyangiitis (22.4% of cases) and hypersensitivity forms (14.1%). Idiopathic/undefined forms accounted for 44.9% of cases, and miscellaneous causes accounted for 18.6%. In-hospital death or need for heart transplantation (HTx) occurred in 23 patients (14.7%; 22 deaths and 1 HTx), despite 43.6% being treated with temporary mechanical circulatory support and 92.3% being treated with immunosuppressive agents. Estimated rates of death or HTx at 1 and 3 years were 19.0% and 23.8%. Increased age, decreased left ventricular ejection fraction on admission, and no immunosuppressive therapy during hospitalization were independent predictors of death or HTx. A nonsignificant higher occurrence of deaths or HTx was observed in the hypersensitivity form (46.1%) compared with the eosinophilic granulomatosis with polyangiitis-associated form (13.1%) at 3 years (P=0.15). CONCLUSIONS: Acute EM can often present without peripheral eosinophilia, and rates of in-hospital and midterm mortality or HTx are high. Endomyocardial biopsy is required to reach the final diagnosis of EM because relying on peripheral eosinophilia can lead to missing diagnosis. In-hospital immunosuppression is associated with HTx-free survival, although tailored immunosuppressive therapies are needed to improve outcomes.